Effects of SVF and exosome in covid-19 patients with acute respiratory distress syndrome

Effect of stromal vascular fraction (SVF), blood and condition medium derived exosomes on treatment of covid-19 patients with Acute Respiratory Distress Syndrome(ARDS)/ clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200510047385N1

Enrollment

Registered

2020-07-07

Start date

2020-06-30

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19.

Interventions

Intervention group: Patients are divided into four control and experimental groups (60 patients: 15 patients in each group). Routine control group with routine treatment Receiver group SVF autologous

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: covid19 patients hospitalized in the ICU, which includes all confirmatory tests – Satisfaction in studying

Exclusion criteria

Exclusion criteria: History of kidney transplantation History surgery on the lungs The presence of any malignancy Previous active infection Use immunosuppressive and other drugs The presence of autoimmune disease

Design outcomes

Primary

Measure	Time frame
Evaluation of inflammatory status IL1,. Timepoint: per 3 days. Method of measurement: Eliza.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactleila Roshangar

Tabriz University of Medical Sciences

lroshangar@yahoo.com+98 41 3336 3870

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026